Gossamer Bio (NASDAQ:GOSS – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.79) by $2.60, Zacks reports.
Gossamer Bio Price Performance
Gossamer Bio stock traded up $0.63 during mid-day trading on Tuesday, reaching $11.28. The stock had a trading volume of 99,027 shares, compared to its average volume of 236,415. The company has a market capitalization of $68.93 million, a price-to-earnings ratio of -0.20 and a beta of 2.28. The company has a 50-day moving average price of $10.76 and a two-hundred day moving average price of $37.05. Gossamer Bio has a one year low of $8.29 and a one year high of $309.60.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. Chardan Capital reaffirmed a “buy” rating on shares of Gossamer Bio in a research note on Monday, October 26th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Tuesday, July 28th. Finally, Weiss Ratings lowered Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $256.00.
Check Out Our Latest Analysis on GOSS
About Gossamer Bio
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Further Reading
- Five stocks we like better than Gossamer Bio
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
